Want to receive updates for this keyword?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Upsaint gallen
• keyword#1
Stéphanie Delpous, Ghislain Benhessa, Alexandre Bilalis, Catherine Tomasetto, Carole Mathelin
On April 27th 2011, the French Supreme Administrative Court (Conseil d'État) granted the Recommendations for Good Practice set out by the French National Authority for Health (Haute Autorité de santé--[HAS]) a legal status, considering that they "must be regarded as (…) decisions which may be subject to an action for annulment". The judge came to this conclusion through a quasi-syllogistic reasoning. Firstly, the French Code of Medical Ethics requires physicians to care for their patients in accordance with established scientific knowledge...
March 2014: Bulletin du Cancer
#2
REVIEW
Serge Koscielny
PURPOSE OF REVIEW: We critically review the methods used in microarray profiling, the reliability of published genomic signatures and the design of ongoing trials based on two of these signatures. RECENT FINDINGS: The main limitations of microarray prognostic signatures are known: instability of gene lists, overoptimistic performance indicators and inadequate validation. Two commercially available gene expression-based prognostic tests (MammaPrint and OncotypeDX) are currently being assessed in two large randomized clinical trials...
February 2008: Current Opinion in Obstetrics & Gynecology
#3
REVIEW
A Lesur, B Cutuli, M-P Teissier, E Luporsi
After a dominant role for more than 30 years, tamoxifen has been progressively replaced by aromatase inhibitors as adjuvant treatment for breast cancer in the menopaused woman. We present here a recall of the mechanisms of action involved together with a review of clinical trials leading to the current situation. Giving trial results in detail, we discuss the current evidence as well as open questions. The populations concerned and trial methodologies are analyzed. Comparative tolerance is detailed. Several questions remain open, either due to the lack of evidence to be obtained from ongoing trials or sufficient follow-up...
June 2006: Journal de Gynécologie, Obstétrique et Biologie de la Reproduction
#4
RANDOMIZED CONTROLLED TRIAL
Fabrice Andre, Ahmed Khalil, Khemaies Slimane, Christophe Massard, Marie Christine Mathieu, Stéphane Vignot, Hazem Assi, Suzette Delaloge, Marc Spielmann
PURPOSE: We have evaluated whether the mitotic index could predict the benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer who are eligible for adjuvant chemotherapy according to Saint Gallen guidelines. PATIENTS AND METHODS: A total of 937 patients from a single institution were included in two randomized trials that compared adjuvant anthracycline-based chemotherapy with no chemotherapy. These patients account for 83% of the overall population included in these trials...
May 1, 2005: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#5
C WEGELIN
No abstract text is available yet for this article.
1950: Gesnerus
#6
P SCHYNDER
No abstract text is available yet for this article.
1961: Archives Suisses de Neurologie, Neurochirurgie et de Psychiatrie
#7
U PFANDLER, E SCHNYDER
No abstract text is available yet for this article.
December 1960: Journal de Génétique Humaine
#8
A RAITZIN
No abstract text is available yet for this article.
April 17, 1958: La Semana Médica
#9
Joseph Gligorov, Philippe Beuzeboc
No abstract text is available yet for this article.
March 2003: Bulletin du Cancer
#10
P Kerbrat, M Namer
No abstract text is available yet for this article.
June 1998: Bulletin du Cancer
#11
(no author information available yet)
No abstract text is available yet for this article.
1993: Recent Results in Cancer Research
1
Fetching more papers... 
